Last reviewed · How we verify
Exparel
At a glance
| Generic name | Exparel |
|---|---|
| Also known as | SKY0402, Bupivacaine liposome extended-release injectable suspension, bupivacaine liposome injectable suspension, Liposomal bupivacaine, Bupivacaine Liposome |
| Sponsor | University of Tennessee |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG) (PHASE4)
- Liposomal Bupivacaine With Standard Bupivacaine Versus Dexmedetomidine With Standard Bupivacaine (PHASE3)
- A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery (PHASE2)
- Evaluation of Pain Management After Surgery When Using Exparel in the Pediatric Population (PHASE2)
- EXPAREL or Lidocane as Local Anesthetic in Patients Undergoing Pleuroscopy With Pleural Biopsy and Indwelling Pleural Catheter Placement (PHASE2)
- Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery (PHASE3)
- Efficacy of EXPAREL vs. Bupivacaine (PHASE3)
- Exparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Exparel CI brief — competitive landscape report
- Exparel updates RSS · CI watch RSS
- University of Tennessee portfolio CI